Table 4.

Univariate analysis of factors associated with poor prognosis in patients with AE.

Variable	12-Month prognosis		24-Month prognosis
	OR (95% CI)	P -value	OR (95% CI)	P -value
Age	0.96 (0.94–0.99)	0.021	0.95 (0.91–0.99)	0.014
Sex, female,	0.71 (0.27–1.83)	0.476	0.96 (0.30–3.10)	0.951
MRS score at study entry	0.44 (0.20–0.95)	0.036	0.89 (0.38–2.06)	0.786
NMDAR-Abs	0.67 (0.26–1.76)	0.419	0.43 (0.13–1.43)	0.170
LGI-1-Abs	0.29 (0.08–1.04)	0.057	0.20 (0.02–1.61)	0.130
Albumin	1.00 (0.90–1.11)	1.000	1.09 (0.96–1.23)	0.179
First-line immunotherapy
Steroids	0.98 (0.37–2.60)	0.971	0.87 (0.26–2.89)	0.816
IVIG	1.81 (0.43–7.63)	0.422	2.64 (0.57–12.16)	0.214
Combined	0.81 (0.32–2.07)	0.664	0.71 (0.22–2.26)	0.556
Second-line immunotherapy	0.90 (0.23–3.48)	0.877	0.72 (0.14–3.66)	0.694
First-line treatment response	4.82 (1.63–14.25)	0.004	6.80 (1.41–32.86)	0.017

mRS, modified Rankin scale; NMDAR, N-methyl-D-aspartate receptor; LGI-1, leucine-rich glioma inactivated protein 1; IVIG, intravenous immunoglobulins.